Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Blood Adv. 2020 Mar 10;4(5):819-829. doi: 10.1182/bloodadvances.2019000844.
Blood Adv. 2020.
PMID: 32126142
Free PMC article.